IN2014DN09221A - - Google Patents
Info
- Publication number
- IN2014DN09221A IN2014DN09221A IN9221DEN2014A IN2014DN09221A IN 2014DN09221 A IN2014DN09221 A IN 2014DN09221A IN 9221DEN2014 A IN9221DEN2014 A IN 9221DEN2014A IN 2014DN09221 A IN2014DN09221 A IN 2014DN09221A
- Authority
- IN
- India
- Prior art keywords
- inhibitor
- chk1
- compounds
- present
- kinase function
- Prior art date
Links
- 102000006459 Checkpoint Kinase 1 Human genes 0.000 abstract 5
- 108010019244 Checkpoint Kinase 1 Proteins 0.000 abstract 5
- 239000003112 inhibitor Substances 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 3
- 108010022394 Threonine synthase Proteins 0.000 abstract 2
- 102000005497 Thymidylate Synthase Human genes 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 102000052567 Anaphase-Promoting Complex-Cyclosome Apc1 Subunit Human genes 0.000 abstract 1
- 108700004581 Anaphase-Promoting Complex-Cyclosome Apc1 Subunit Proteins 0.000 abstract 1
- 102000003915 DNA Topoisomerases Human genes 0.000 abstract 1
- 108090000323 DNA Topoisomerases Proteins 0.000 abstract 1
- 230000005778 DNA damage Effects 0.000 abstract 1
- 231100000277 DNA damage Toxicity 0.000 abstract 1
- 230000005971 DNA damage repair Effects 0.000 abstract 1
- 239000012623 DNA damaging agent Substances 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 abstract 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 abstract 1
- 230000001668 ameliorated effect Effects 0.000 abstract 1
- 230000000340 anti-metabolite Effects 0.000 abstract 1
- 229940100197 antimetabolite Drugs 0.000 abstract 1
- 239000002256 antimetabolite Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000011278 mitosis Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The present invention pertains gen erally to the field of therapeutic compounds. More specifically the present invention pertains to 5-[[4- [[morpholin-2 -yljmethylamino] -5- (trifluoro - methyl)-2-pyridyl]amino]pyrazine-2-carbonitrile compounds (referred to herein as 'TFM com pounds') which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present in vention also pertains to pharmaceutical composi tions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the in hibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., op tionally in combination with another agent, for ex ample, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or a thymidylate synthase (TS) inhibitor; (d) a mi crotubule targeted agent; (e) ionising radiation; (f) an inhibitor of a mitosis regulator or a mitotic checkpoint regulator; (g) an inhibitor of a DNA damage signal transducer; or (h) an inhibitor of a DNA damage repair enzyme.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261647200P | 2012-05-15 | 2012-05-15 | |
| PCT/GB2013/051233 WO2013171470A1 (en) | 2012-05-15 | 2013-05-14 | 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN09221A true IN2014DN09221A (en) | 2015-07-10 |
Family
ID=48468659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN9221DEN2014 IN2014DN09221A (en) | 2012-05-15 | 2013-05-14 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US9663503B2 (en) |
| EP (2) | EP3210980B1 (en) |
| JP (2) | JP6027230B2 (en) |
| KR (6) | KR102635954B1 (en) |
| CN (2) | CN104302635B (en) |
| AU (2) | AU2013261605B2 (en) |
| BR (1) | BR112014026801B1 (en) |
| CA (1) | CA2870837C (en) |
| DK (1) | DK2855448T3 (en) |
| ES (2) | ES2624307T3 (en) |
| IL (1) | IL235133A (en) |
| IN (1) | IN2014DN09221A (en) |
| MX (1) | MX358819B (en) |
| NZ (1) | NZ702050A (en) |
| PL (1) | PL2855448T3 (en) |
| RU (1) | RU2659786C2 (en) |
| SG (1) | SG11201407238VA (en) |
| WO (1) | WO2013171470A1 (en) |
| ZA (1) | ZA201408452B (en) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013068755A1 (en) | 2011-11-09 | 2013-05-16 | Cancer Research Technology Limited | 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use |
| JP6027230B2 (en) * | 2012-05-15 | 2016-11-16 | キャンサー・リサーチ・テクノロジー・リミテッド | 5-[[4-[[morpholin-2-yl] methylamino] -5- (trifluoromethyl) -2-pyridyl] amino] pyrazine-2-carbonitrile and its therapeutic use |
| LT3418281T (en) | 2012-12-07 | 2021-01-11 | Vertex Pharmaceuticals Inc. | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of atr kinase for the treatment of cancer diseases |
| WO2014143240A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
| HUE046727T2 (en) | 2013-12-06 | 2020-03-30 | Vertex Pharma | 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof |
| ES2777608T3 (en) | 2014-06-05 | 2020-08-05 | Vertex Pharma | Radiolabeled derivatives of a 2-amino-6-fluoro-N- [5-fluoro-pyridin-3-yl] -pyrazolo [1,5-a] pyrimidine-3-carboxamide compound useful as ATR kinase inhibitors, the preparation of said compound and different solid forms of it |
| US11179394B2 (en) * | 2014-06-17 | 2021-11-23 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of Chk1 and ATR inhibitors |
| US11464774B2 (en) | 2015-09-30 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
| WO2018094325A1 (en) * | 2016-11-18 | 2018-05-24 | The Trustees Of Columbia University In The City Of New York | Therapeutic modulation of oncogenes by pharmacologic top2 targeting for cancer |
| KR20190130621A (en) * | 2017-03-31 | 2019-11-22 | 시애틀 지네틱스, 인크. | Combination of CHK1 Inhibitors and WEE1 Inhibitors |
| WO2018191299A1 (en) * | 2017-04-10 | 2018-10-18 | Sierra Oncology, Inc. | Chk1(sra737)wee1 inhibitor combination methods of inhibiting tumor growth |
| MX2019012176A (en) * | 2017-04-10 | 2020-02-19 | Sierra Oncology Inc | Chk1 (sra737)/parpi combination methods of inhibiting tumor growth. |
| AU2018278336A1 (en) * | 2017-06-01 | 2020-01-16 | Crt Pioneer Fund Lp | Biomarkers and patient selection strategies |
| CN107266897B (en) * | 2017-08-04 | 2019-05-14 | 上海跃贝新材料科技股份有限公司 | A kind of low viscosity mineral enhancing PC/PET alloy material and preparation method thereof |
| JP2021514979A (en) * | 2018-02-26 | 2021-06-17 | シエラ オンコロジー， インコーポレイテッド | Treatment of cancer containing CHK1 inhibitors |
| EP3914284A4 (en) * | 2019-01-25 | 2022-10-26 | Numedii, Inc. | METHOD FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS |
| CA3135165A1 (en) * | 2019-03-28 | 2020-10-01 | Sierra Oncology, Inc. | Methods of treating cancer with chk1 inhibitors |
| AU2020274164A1 (en) * | 2019-05-14 | 2021-11-25 | Sierra Oncology, Inc. | Methods of treating cancer using Chk1 inhibitors |
| CN110872277B (en) * | 2019-11-14 | 2021-06-04 | 浙江大学 | N-substituted aromatic ring-2-aminopyrimidine compounds and application thereof |
| CN110684083B (en) * | 2019-12-06 | 2020-05-15 | 北京诺赛启研再生医学研究院有限公司 | Conjugate II for inhibiting melanin synthesis and application thereof in medicines and cosmetics |
| CN110680928B (en) * | 2019-12-06 | 2020-04-28 | 深圳前海港影生物科技有限公司 | Conjugate for inhibiting melanin synthesis and application thereof in medicines and cosmetics |
| CN120441567A (en) * | 2020-04-07 | 2025-08-08 | Crt先锋基金有限公司 | Synthesis method of CHK1 inhibitor |
| WO2023021328A1 (en) * | 2021-08-17 | 2023-02-23 | Bellus Health Cough Inc. | Preparation of a p2x3 antagonist |
| WO2025101691A1 (en) | 2023-11-08 | 2025-05-15 | Exelixis, Inc. | Methods for treating cancer using compounds that inhibit pkmyt1 |
| WO2026108771A2 (en) | 2024-11-19 | 2026-05-28 | Groovy Medicine (Hangzhou) Ltd. | Substituted heteroaromatic compounds as inhibitors of checkpoint kinase 1 and notch signaling pathway and uses thereof |
| WO2026108769A1 (en) * | 2024-11-19 | 2026-05-28 | Groovy Medicine (Hangzhou) Ltd. | Substituted 2- [ (5-cyanopyrazin-2-yl) amino] pyridines, their prodrugs and uses thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773778A (en) | 1972-01-24 | 1973-11-20 | Squibb & Sons Inc | Sulfur derivatives of pyrazolo (3,4-b)pyridines |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| PL188959B1 (en) | 1995-07-06 | 2005-05-31 | Novartis Ag | Pyrollepyrimidines and methods of obtaining them |
| JP4637481B2 (en) | 2001-10-19 | 2011-02-23 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 2-phenylbenzimidazole and imidazo- [4,5] -pyridine as CDS1 / CHK2 inhibitors and adjuvants for chemotherapy or radiotherapy in cancer treatment |
| IL161576A0 (en) | 2001-10-26 | 2004-09-27 | Aventis Pharma Inc | Benzimidazoles and analogues and their use as protein kinases inhibitors |
| CA2464934A1 (en) | 2001-10-31 | 2003-05-08 | Bayer Healthcare Ag | Pyrimido [4,5-b] indole derivatives |
| AU2003234464B2 (en) * | 2002-05-03 | 2009-06-04 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| AU2003243318A1 (en) * | 2002-05-29 | 2003-12-19 | Millennium Pharmaceuticals, Inc. | Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer |
| AU2004260689B8 (en) | 2003-07-29 | 2008-05-15 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| WO2005034869A2 (en) | 2003-10-08 | 2005-04-21 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| WO2005037825A2 (en) | 2003-10-14 | 2005-04-28 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein kinase inhibitors |
| WO2005037285A1 (en) | 2003-10-16 | 2005-04-28 | Chiron Corporation | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer |
| US20050096324A1 (en) | 2003-11-05 | 2005-05-05 | Zhi-Fu Tao | Macrocyclic kinase inhibitors |
| US7163939B2 (en) | 2003-11-05 | 2007-01-16 | Abbott Laboratories | Macrocyclic kinase inhibitors |
| US7642354B2 (en) | 2004-04-13 | 2010-01-05 | Icagen, Inc. | Polycyclic pyrazines as potassium ion channel modulators |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| CN101189239A (en) | 2005-04-28 | 2008-05-28 | 休普基因公司 | protein kinase inhibitor |
| EP1899322B1 (en) | 2005-06-28 | 2009-09-02 | Sanofi-Aventis | Isoquinoline derivatives as inhibitors of rho-kinase |
| PE20070335A1 (en) | 2005-08-30 | 2007-04-21 | Novartis Ag | SUBSTITUTE BENZIMIDAZOLES AND METHODS FOR THEIR PREPARATION |
| PE20070543A1 (en) | 2005-10-06 | 2007-06-14 | Schering Corp | PYRAZOLOPYRIMIDINES AS PROTEIN KINAS INHIBITORS |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| GB0616747D0 (en) * | 2006-08-24 | 2006-10-04 | Astrazeneca Ab | Novel compounds |
| AU2007338410B2 (en) | 2006-12-27 | 2012-08-16 | Sanofi-Aventis | Cycloalkylamine substituted isoquinoline derivatives |
| EP2134689B1 (en) * | 2007-03-16 | 2014-04-23 | The Scripps Research Institute | Inhibitors of focal adhesion kinase |
| WO2008117050A1 (en) | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer |
| US8618121B2 (en) | 2007-07-02 | 2013-12-31 | Cancer Research Technology Limited | 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors |
| GB0719644D0 (en) * | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB0803018D0 (en) | 2008-02-19 | 2008-03-26 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| WO2013068755A1 (en) | 2011-11-09 | 2013-05-16 | Cancer Research Technology Limited | 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use |
| JP6027230B2 (en) | 2012-05-15 | 2016-11-16 | キャンサー・リサーチ・テクノロジー・リミテッド | 5-[[4-[[morpholin-2-yl] methylamino] -5- (trifluoromethyl) -2-pyridyl] amino] pyrazine-2-carbonitrile and its therapeutic use |
-
2013
- 2013-05-14 JP JP2015512120A patent/JP6027230B2/en active Active
- 2013-05-14 KR KR1020227037439A patent/KR102635954B1/en active Active
- 2013-05-14 KR KR1020217041302A patent/KR20210156333A/en not_active Ceased
- 2013-05-14 KR KR1020147031572A patent/KR102090792B1/en active Active
- 2013-05-14 AU AU2013261605A patent/AU2013261605B2/en active Active
- 2013-05-14 DK DK13723910.9T patent/DK2855448T3/en active
- 2013-05-14 WO PCT/GB2013/051233 patent/WO2013171470A1/en not_active Ceased
- 2013-05-14 ES ES13723910.9T patent/ES2624307T3/en active Active
- 2013-05-14 IN IN9221DEN2014 patent/IN2014DN09221A/en unknown
- 2013-05-14 EP EP17152400.2A patent/EP3210980B1/en active Active
- 2013-05-14 EP EP13723910.9A patent/EP2855448B1/en active Active
- 2013-05-14 SG SG11201407238VA patent/SG11201407238VA/en unknown
- 2013-05-14 KR KR1020207007411A patent/KR102246265B1/en active Active
- 2013-05-14 ES ES17152400T patent/ES2981584T3/en active Active
- 2013-05-14 KR KR1020247004407A patent/KR20240023685A/en not_active Withdrawn
- 2013-05-14 RU RU2014147105A patent/RU2659786C2/en active
- 2013-05-14 KR KR1020217012299A patent/KR102341637B1/en active Active
- 2013-05-14 PL PL13723910T patent/PL2855448T3/en unknown
- 2013-05-14 US US14/396,338 patent/US9663503B2/en active Active
- 2013-05-14 CN CN201380025541.3A patent/CN104302635B/en active Active
- 2013-05-14 NZ NZ702050A patent/NZ702050A/en unknown
- 2013-05-14 BR BR112014026801-0A patent/BR112014026801B1/en active IP Right Grant
- 2013-05-14 MX MX2014012881A patent/MX358819B/en active IP Right Grant
- 2013-05-14 CN CN201610652725.8A patent/CN106279142B/en active Active
- 2013-05-14 CA CA2870837A patent/CA2870837C/en active Active
-
2014
- 2014-10-19 IL IL235133A patent/IL235133A/en active IP Right Grant
- 2014-11-18 ZA ZA2014/08452A patent/ZA201408452B/en unknown
-
2016
- 2016-10-13 JP JP2016201383A patent/JP6362652B2/en active Active
-
2017
- 2017-05-04 US US15/587,270 patent/US10259806B2/en active Active
- 2017-11-28 AU AU2017268508A patent/AU2017268508C1/en active Active
-
2020
- 2020-12-17 US US17/124,606 patent/US11787792B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX358819B (en) | 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridy l]amino]pyrazine-2-carbonitrile and therapeutic uses thereof. | |
| PH12021550019A1 (en) | Fused pyrazine derivatives as a2a / a2b inhibitors | |
| ZA201906269B (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| JOP20200277B1 (en) | RIP1 inhibitors and methods for their preparation and use | |
| MX2014009219A (en) | Purinone compounds as kinase inhibitors. | |
| PH12015501067A1 (en) | Pyrrolopyrimidine compounds as kinase inhibitors | |
| BR112012022513A2 (en) | piperidin-4-yl azetidine derivatives as jak1 inhibitors | |
| MX342509B (en) | Substituted indazole derivatives active as kinase inhibitors. | |
| PH12015500940A1 (en) | Bruton`s tyrosine kinase inhibitors | |
| TN2016000094A1 (en) | Inhibitors of bruton's tyrosine kinase. | |
| BR112014010938A2 (en) | 5- (pyridin-2-yl-amino) -pyrazine-2-carbonitrile compounds and their therapeutic use | |
| PH12014500351B1 (en) | COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS | |
| MX369589B (en) | Novel benzimidazole derivatives as kinase inhibitors. | |
| CA2861804C (en) | 2-benzyl,3(pyrimidin-2-yl)substituted pyrazoles useful as sgc stimulators | |
| GB201104267D0 (en) | Pyrrolopyridineamino derivatives | |
| MX2015012431A (en) | Pyrrole amide inhibitors. | |
| WO2014179562A8 (en) | 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof | |
| PH12012502391A1 (en) | 2,4- diaryl - substituted [1,8] naphthyridines as kinase inhibitors for use against cancer | |
| MX2009010034A (en) | Substituted pyrimidodiazepines useful as plk1 inhibitors. | |
| MX2014002486A (en) | Compounds and compositions as pdgfr kinase inhibitors. | |
| PH12013501136A1 (en) | Lysophosphatidic acid receptor antagonists and uses thereof | |
| BR112013008140A8 (en) | "IMIDAZOTRIAZINONE COMPOUNDS". | |
| MX362855B (en) | Quinazolinone derivatives as parp inhibitors. | |
| MX2020012376A (en) | Fused pyrimidine derivatives as a2a / a2b inhibitors. | |
| PH12013501355A1 (en) | (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases |